Global Circulating Tumour DNA (ctDNA) Testing Market Research Report 2024

Publication ID:

PB508241744

Publication Date:

August 19, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. Most DNA is inside a cell鈥檚 nucleus. As a tumor grows, cells die and are replaced by new ones. The dead cells get broken down and their contents, including DNA, are released into the bloodstream. ctDNA are small pieces of DNA, usually comprising fewer than 200 building blocks (nucleotides) in length.The quantity of ctDNA varies among individuals and depends on the type of tumor, its location, and for cancerous tumors, the cancer stage.Circulating-tumor DNA (ctDNA) refers to fragments of DNA derived from tumor cells and circulating in the blood together with cell-free DNA from other sources. Circulating tumor DNA (ctDNA) analyses are minimally invasive and accessible for risk stratification or treatment response monitoring of cancer patients. Compared to tumor biopsy analysis, they are not only less invasive, but also provide a more representative picture, allowing capturing both tumor heterogeneity and multiple tumor sites.
The global Circulating Tumour DNA (ctDNA) Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Circulating Tumour DNA (ctDNA) Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Circulating Tumour DNA (ctDNA) Testing in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Circulating Tumour DNA (ctDNA) Testing include Nexomics, Roche, ORIOMICS, Signatera, Illumina, Sysmex Corporation, Bio-Rad, Biocartis and QIAGEN, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumour DNA (ctDNA) Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumour DNA (ctDNA) Testing.
Report Scope
The Circulating Tumour DNA (ctDNA) Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Circulating Tumour DNA (ctDNA) Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumour DNA (ctDNA) Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Nexomics
Roche
ORIOMICS
Signatera
Illumina
Sysmex Corporation
Bio-Rad
Biocartis
QIAGEN
GuardantHealth
GSK plc
AstraZeneca
NeoGenomics Laboratories
AmoyDx
Annoroad
Burning Rock Biotech
Segment by Type
Gastric Cancer Methylation Screening
Esophageal Cancer Methylation Screening
Colorectal Cancer Methylation Screening
Lung Cancer Methylation Screening
Liver Cancer Methylation Screening
Other Cancer Screening
Segment by Application
Hospital
Medical Center
Laboratory
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumour DNA (ctDNA) Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Gastric Cancer Methylation Screening
1.2.3 Esophageal Cancer Methylation Screening
1.2.4 Colorectal Cancer Methylation Screening
1.2.5 Lung Cancer Methylation Screening
1.2.6 Liver Cancer Methylation Screening
1.2.7 Other Cancer Screening
1.3 Market by Application
1.3.1 Global Circulating Tumour DNA (ctDNA) Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Medical Center
1.3.4 Laboratory
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumour DNA (ctDNA) Testing Market Perspective (2019-2030)
2.2 Circulating Tumour DNA (ctDNA) Testing Growth Trends by Region
2.2.1 Global Circulating Tumour DNA (ctDNA) Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Circulating Tumour DNA (ctDNA) Testing Historic Market Size by Region (2019-2024)
2.2.3 Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Region (2025-2030)
2.3 Circulating Tumour DNA (ctDNA) Testing Market Dynamics
2.3.1 Circulating Tumour DNA (ctDNA) Testing Industry Trends
2.3.2 Circulating Tumour DNA (ctDNA) Testing Market Drivers
2.3.3 Circulating Tumour DNA (ctDNA) Testing Market Challenges
2.3.4 Circulating Tumour DNA (ctDNA) Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumour DNA (ctDNA) Testing Players by Revenue
3.1.1 Global Top Circulating Tumour DNA (ctDNA) Testing Players by Revenue (2019-2024)
3.1.2 Global Circulating Tumour DNA (ctDNA) Testing Revenue Market Share by Players (2019-2024)
3.2 Global Circulating Tumour DNA (ctDNA) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumour DNA (ctDNA) Testing Revenue
3.4 Global Circulating Tumour DNA (ctDNA) Testing Market Concentration Ratio
3.4.1 Global Circulating Tumour DNA (ctDNA) Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumour DNA (ctDNA) Testing Revenue in 2023
3.5 Circulating Tumour DNA (ctDNA) Testing Key Players Head office and Area Served
3.6 Key Players Circulating Tumour DNA (ctDNA) Testing Product Solution and Service
3.7 Date of Enter into Circulating Tumour DNA (ctDNA) Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumour DNA (ctDNA) Testing Breakdown Data by Type
4.1 Global Circulating Tumour DNA (ctDNA) Testing Historic Market Size by Type (2019-2024)
4.2 Global Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Type (2025-2030)
5 Circulating Tumour DNA (ctDNA) Testing Breakdown Data by Application
5.1 Global Circulating Tumour DNA (ctDNA) Testing Historic Market Size by Application (2019-2024)
5.2 Global Circulating Tumour DNA (ctDNA) Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Circulating Tumour DNA (ctDNA) Testing Market Size (2019-2030)
6.2 North America Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2019-2024)
6.4 North America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumour DNA (ctDNA) Testing Market Size (2019-2030)
7.2 Europe Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2019-2024)
7.4 Europe Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size (2019-2030)
8.2 Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific Circulating Tumour DNA (ctDNA) Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumour DNA (ctDNA) Testing Market Size (2019-2030)
9.2 Latin America Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2019-2024)
9.4 Latin America Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size (2019-2030)
10.2 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa Circulating Tumour DNA (ctDNA) Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nexomics
11.1.1 Nexomics Company Detail
11.1.2 Nexomics Business Overview
11.1.3 Nexomics Circulating Tumour DNA (ctDNA) Testing Introduction
11.1.4 Nexomics Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.1.5 Nexomics Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Circulating Tumour DNA (ctDNA) Testing Introduction
11.2.4 Roche Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.2.5 Roche Recent Development
11.3 ORIOMICS
11.3.1 ORIOMICS Company Detail
11.3.2 ORIOMICS Business Overview
11.3.3 ORIOMICS Circulating Tumour DNA (ctDNA) Testing Introduction
11.3.4 ORIOMICS Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.3.5 ORIOMICS Recent Development
11.4 Signatera
11.4.1 Signatera Company Detail
11.4.2 Signatera Business Overview
11.4.3 Signatera Circulating Tumour DNA (ctDNA) Testing Introduction
11.4.4 Signatera Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.4.5 Signatera Recent Development
11.5 Illumina
11.5.1 Illumina Company Detail
11.5.2 Illumina Business Overview
11.5.3 Illumina Circulating Tumour DNA (ctDNA) Testing Introduction
11.5.4 Illumina Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.5.5 Illumina Recent Development
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Detail
11.6.2 Sysmex Corporation Business Overview
11.6.3 Sysmex Corporation Circulating Tumour DNA (ctDNA) Testing Introduction
11.6.4 Sysmex Corporation Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.6.5 Sysmex Corporation Recent Development
11.7 Bio-Rad
11.7.1 Bio-Rad Company Detail
11.7.2 Bio-Rad Business Overview
11.7.3 Bio-Rad Circulating Tumour DNA (ctDNA) Testing Introduction
11.7.4 Bio-Rad Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.7.5 Bio-Rad Recent Development
11.8 Biocartis
11.8.1 Biocartis Company Detail
11.8.2 Biocartis Business Overview
11.8.3 Biocartis Circulating Tumour DNA (ctDNA) Testing Introduction
11.8.4 Biocartis Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.8.5 Biocartis Recent Development
11.9 QIAGEN
11.9.1 QIAGEN Company Detail
11.9.2 QIAGEN Business Overview
11.9.3 QIAGEN Circulating Tumour DNA (ctDNA) Testing Introduction
11.9.4 QIAGEN Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.9.5 QIAGEN Recent Development
11.10 GuardantHealth
11.10.1 GuardantHealth Company Detail
11.10.2 GuardantHealth Business Overview
11.10.3 GuardantHealth Circulating Tumour DNA (ctDNA) Testing Introduction
11.10.4 GuardantHealth Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.10.5 GuardantHealth Recent Development
11.11 GSK plc
11.11.1 GSK plc Company Detail
11.11.2 GSK plc Business Overview
11.11.3 GSK plc Circulating Tumour DNA (ctDNA) Testing Introduction
11.11.4 GSK plc Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.11.5 GSK plc Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Detail
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Circulating Tumour DNA (ctDNA) Testing Introduction
11.12.4 AstraZeneca Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.12.5 AstraZeneca Recent Development
11.13 NeoGenomics Laboratories
11.13.1 NeoGenomics Laboratories Company Detail
11.13.2 NeoGenomics Laboratories Business Overview
11.13.3 NeoGenomics Laboratories Circulating Tumour DNA (ctDNA) Testing Introduction
11.13.4 NeoGenomics Laboratories Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.13.5 NeoGenomics Laboratories Recent Development
11.14 AmoyDx
11.14.1 AmoyDx Company Detail
11.14.2 AmoyDx Business Overview
11.14.3 AmoyDx Circulating Tumour DNA (ctDNA) Testing Introduction
11.14.4 AmoyDx Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.14.5 AmoyDx Recent Development
11.15 Annoroad
11.15.1 Annoroad Company Detail
11.15.2 Annoroad Business Overview
11.15.3 Annoroad Circulating Tumour DNA (ctDNA) Testing Introduction
11.15.4 Annoroad Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.15.5 Annoroad Recent Development
11.16 Burning Rock Biotech
11.16.1 Burning Rock Biotech Company Detail
11.16.2 Burning Rock Biotech Business Overview
11.16.3 Burning Rock Biotech Circulating Tumour DNA (ctDNA) Testing Introduction
11.16.4 Burning Rock Biotech Revenue in Circulating Tumour DNA (ctDNA) Testing Business (2019-2024)
11.16.5 Burning Rock Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Nexomics
Roche
ORIOMICS
Signatera
Illumina
Sysmex Corporation
Bio-Rad
Biocartis
QIAGEN
GuardantHealth
GSK plc
AstraZeneca
NeoGenomics Laboratories
AmoyDx
Annoroad
Burning Rock Biotech

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂